| 摘要: |
| 目的 探讨丁螺环酮联合草酸艾司西酞普兰治疗抑郁症的增效作用和安全性。方法 选取符合ICD-10 抑郁发作
诊断标准，经草酸艾司西酞普兰足量（20mg/d）、足疗程（6周）治疗未获得痊愈的45 例抑郁症患者，加用丁螺环酮15~60mg/d，观察8周，并分别在治疗前、治疗后第1、4、8周末分别评估汉密尔顿抑郁量表（HAMD）和汉密尔顿焦虑量表（HAMA），以第1周末HAMA 评分≤7分为界，分为焦虑控制组（HAMA 评分≤7 分）和焦虑未控制组（HAMA 评分＞7 分）；以8周末HAMD≤7分为标准，分为获得痊愈组（HAMD≤7 分）和未获得痊愈组（HAMD＞7 分）；并在治疗第1、4、8周末分别评估不良反应。结果 在治疗第4周，获得痊愈20 例（44.4%），第8 周末获得痊愈25 例（55.5%）。治疗后第4、8 周，获得痊愈组的患者HAMA 评分明显低于未获得痊愈组（P＜0.05）。治疗后第1、4周，焦虑控制组和焦虑未控制组患者HAMD 评分比较差异无统计学意义，治疗后第8 周，两组患者HAMD 评分
比较差异有统计学意义（P＜0.05）。不良反应以口干（40.0%）、便秘（36.9%）及乏力（13.3%）为多见。结论 经草酸艾司西酞普兰足量、足疗程治疗后仍未彻底痊愈的患者加用丁螺环酮可进一步获得疗效，提高痊愈率,安全性良好。 |
| 关键词: 抑郁症 草酸艾司西酞普兰 丁螺环酮 治疗 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Enhancing effects and safety of buspirone in combination with escitalopram for patients with depression |
|
TAN Yunfei,LIAO Zhengluan,QIU Yaju,ZHU Junpeng,WANG Yu,WANG Xinwei,WANG Hong,SHI Meifang,YU Enyan
|
|
Zhejiang Province People's Hospital
|
| Abstract: |
| Objective To investigate the enhancing effects and safety of buspirone in combination with escitalopram for patients with depression. Methods Forty eight depressive patients with incompleted recovery after administration of escitalopram(20mg/d) over 6 weeks were enrolled in the study. Patients received buspirone(15-60mg/d) along with an optimal dose of escitalopram for 8 weeks．Patients were evaluated with Hamilton Depression Scale (HAMD-17) and Hamilton Anxiety Scale
(HAMA-14) at the end of 1st, 4th and 8th week, Adverse effects were assessed with Treatment Emergent Symptom Scale (TESS)at the end of 1st, 4th and 8th week. By the end of week 8, patients were grouped in A (Remission: HAMD≤7) and B (Non-remission:HAMD≥7), While by the end of week 1, patients were grouped inC (HAMA ≤ 7) andD (HAMA≥7), Results Of 48 enrolled patients, 45 patients completed the study while the remaining 3 dropped out. At the end of the 4th week, 20 patients(44.4%) achieved recovery and by the end of 8th week, 25 patients(55.5%) achieved recovery. The study group scored lower than the control in the HAMA score (P＜0.05). Anxiety patients with signs of recovery at week 1 (HAMA≤7) obtained a lower HAMD score at week 4 and 8 (P＜0.05). The adverse effects included xerostomia(40%), constipation (36.9%) and fatigue(13.3%). Most of patients were tolerated well till the end of the study and no participants drop out due to the adverse effects. Conclusion Depressive
patients treated with buspirone along with escitaloprammay obtain better recovery with the safety. |
| Key words: Depression Escitalopram Buspirone Treatment |
